Breaking News Headlines Today | Ground News

See every side of every news story

cancernetwork.com image

News from cancernetwork.com

Ground News rates cancernetwork.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Is cancernetwork.com credible or reliable? Our Factuality score answers both of those questions. When it comes to cancernetwork.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about cancernetwork.com

Where is cancernetwork.com located?cancernetwork.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top cancernetwork.com News

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

Cancer · Hong Kong

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

73% Center coverage: 30 sources

HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study will…See the Story

Preoperative MRI Offers No Survival Benefit for Early-Stage Breast Cancer Patients

Preoperative MRI Offers No Survival Benefit for Early-Stage Breast Cancer Patients

100% Center coverage: 2 sources

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional recurrence whether or not they underwent preoperative breast magnetic resonance imaging (MRI) in addition to diagnostic mammography to determine the extent of their cancer, according to results from the phase III Alliance A011104/ACRIN 6694 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December …See the Story

No Increased Breast Cancer Risk With Menopausal Estrogen in BRCA Carriers

No Increased Breast Cancer Risk With Menopausal Estrogen in BRCA Carriers

(MedPage Today) — SAN ANTONIO — Menopausal hormone therapy (MHT) did not increase breast cancer risk in women with BRCA mutations, according to a study reported here. In fact, women who used estrogen-only MHT had a significantly lower risk… Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/119005 Author : Publish date : 2025-12-13 22:05:00 Copyright for syndicated content belongs […] The post No Increased Breast Cancer Risk With M…See the Story

Breaking News Topics Related to cancernetwork.com